Mani Foroohar
Stock Analyst at Leerink Partners
(2.62)
# 2,279
Out of 5,090 analysts
172
Total ratings
52.13%
Success rate
1.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Maintains: Underperform | $15 → $18 | $27.70 | -35.02% | 19 | Nov 21, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $9 → $20 | $9.35 | +113.90% | 6 | Oct 7, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Market Perform | $9 → $7 | $3.32 | +110.84% | 13 | Oct 3, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Market Perform | $45 → $10 | $22.26 | -55.08% | 2 | Jul 21, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $7 → $6 | $4.71 | +27.39% | 8 | Feb 28, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $31 → $27 | $10.70 | +152.34% | 9 | Jan 13, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $45 → $72 | $20.28 | +255.03% | 2 | Nov 12, 2024 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $17 | $3.25 | +423.08% | 1 | Nov 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $47 → $49 | $68.48 | -28.45% | 11 | Oct 17, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $47 → $46 | $73.64 | -37.53% | 15 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $22 | $7.49 | +193.72% | 6 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $53 → $62 | $81.68 | -24.09% | 15 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $13.58 | -4.27% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $17.64 | +64.40% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $4 | $5.12 | -21.88% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $13.16 | - | 10 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $8.07 | +284.14% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.41 | +396.45% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $61.44 | -34.90% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $9.61 | +774.09% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $2.42 | +189.26% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $27.09 | +184.24% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $144 → $143 | $458.12 | -68.79% | 11 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $4.88 | +23.08% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $56.88 | +33.61% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.90 | +1,689.47% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $20 | $4.26 | +369.48% | 6 | Jul 23, 2021 |
Moderna
Nov 21, 2025
Maintains: Underperform
Price Target: $15 → $18
Current: $27.70
Upside: -35.02%
Lexeo Therapeutics
Oct 7, 2025
Maintains: Outperform
Price Target: $9 → $20
Current: $9.35
Upside: +113.90%
Rocket Pharmaceuticals
Oct 3, 2025
Maintains: Market Perform
Price Target: $9 → $7
Current: $3.32
Upside: +110.84%
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Market Perform
Price Target: $45 → $10
Current: $22.26
Upside: -55.08%
Recursion Pharmaceuticals
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $4.71
Upside: +27.39%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $10.70
Upside: +152.34%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $20.28
Upside: +255.03%
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $3.25
Upside: +423.08%
Mirum Pharmaceuticals
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $68.48
Upside: -28.45%
BridgeBio Pharma
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $46
Current: $73.64
Upside: -37.53%
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $7.49
Upside: +193.72%
Jul 24, 2024
Upgrades: Outperform
Price Target: $53 → $62
Current: $81.68
Upside: -24.09%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $13.58
Upside: -4.27%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $17.64
Upside: +64.40%
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $5.12
Upside: -21.88%
Mar 6, 2024
Upgrades: Outperform
Price Target: n/a
Current: $13.16
Upside: -
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $8.07
Upside: +284.14%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $1.41
Upside: +396.45%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $61.44
Upside: -34.90%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $9.61
Upside: +774.09%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $2.42
Upside: +189.26%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $27.09
Upside: +184.24%
Jan 23, 2023
Maintains: Market Perform
Price Target: $144 → $143
Current: $458.12
Upside: -68.79%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $4.88
Upside: +23.08%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $56.88
Upside: +33.61%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.90
Upside: +1,689.47%
Jul 23, 2021
Maintains: Market Perform
Price Target: $50 → $20
Current: $4.26
Upside: +369.48%